Yellow Fever Vaccine
Journal: Annals of Internal Medicine (1984)

Diagnosis and Treatment1 April 1984Yellow Fever VaccineRecommendations of the Immunization Practices Advisory CommitteeAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-100-4-540 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractAbstractThese revised Immunization Practices Advisory Committee recommendations on yellow fever vaccine update the 1978 recommendations. Changes have been made to clarify the risks of acquiring yellow fever associated with travel to endemic areas; the precautions necessary for immunization of special groups (infants, pregnant women); procedures for immunization of persons with histories of possible egg allergy; and simultaneous administration of other vaccines.References1. STRODE G ed. Yellow Fever. New York: McGraw Hill Book Company; 1951. Google Scholar2. World Health Organization Expert Committee on Yellow Fever, 3rd Report. Geneva: World Health Organization; 1971. WHO Technical Report Series, no. 4791. Google Scholar3. MONATHCRAVENADJUKIEWICZ TRA. Yellow fever in the Gambia, 1978-1979: epidemiologic aspects with observations on the occurrence of Orungo virus infections. Am J Trop Med Hyg. 1980;29:912-28. CrossrefMedlineGoogle Scholar4. SMITHBURNDURIEUXKOERBER KCR. Yellow Fever Vaccination. Geneva: World Health Organization; 1956. WHO Monograph Series, no. 30. CrossrefGoogle Scholar5. WISSEMANSWEET CB. Immunological studies with group B arthropod-borne viruses: III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am J Trop Med. 1962;11:570-5. CrossrefMedlineGoogle Scholar6. RODHAINHANNOUNJOUSSETRAVISSE FCFP. Isolement du virus de la fièvre jaune à Paris a partir de deux cas humains importés. Bull Soc Pathol Exot. 1979;72:411-5. Google Scholar7. GROOTRIBEIRO HR. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull WHO. 1962;27:699-707. MedlineGoogle Scholar8. POLANDCALISHERMONATHDOWNSMURPHY JCTWK. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull WHO. 1981;59:895-900. MedlineGoogle Scholar9. ROSENZWEIGBABIONEWISSEMAN ERC. Immunological studies with group B arthropod-borne viruses: IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med. 1963;12:230-5. CrossrefMedlineGoogle Scholar10. TAURASOMYERSNAU NME. Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man. J Infect Dis. 1972;126:363-71. CrossrefGoogle Scholar11. FELSENFELDWOLFGYR ORK. Simultaneous vaccination against cholera and yellow fever. Lancet. 1973;1:457-8. CrossrefMedlineGoogle Scholar12. GATEFF C. Acquisitions recentes en matiere d'associations vaccinales. Bull Soc Pathol Exot. 1972;65:784-96. Google Scholar13. KAPLANNELSONSCHONBERGER JDL. The effect of immune globulin on trivalent oral polio and yellow fever vaccinations. Bull WHO. 1984. (In press). MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: ▸From the Immunization Practices Advisory Committee, Centers for Disease Control; Atlanta, Georgia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHealth Advice for International TravelersYellow Fever Vaccine and Avian Leukosis VirusHARRY C. NOTTEBART JR., M.D. 1 April 1984Volume 100, Issue 4Page: 540-542KeywordsAllergy and immunologyFeversInfantsPregnancyVaccines ePublished: 1 December 2008 Issue Published: 1 April 1984 PDF downloadLoading ...